Arcturus Therapeutics (ARCT) to present ARCT-810 poster, more data due this quarter
Rhea-AI Filing Summary
Arcturus Therapeutics Holdings Inc. (ARCT) reports that on August 25, 2026 it will present a scientific poster titled “Impact of ARCT-810 mRNA Therapy on Dietary Intake and Biochemical Data in Adolescents and Adults with Ornithine Transcarbamylase Deficiency” at the 2026 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism in Helsinki, Finland. The company states that additional data and the regulatory plan for the ARCT-810 program are expected to be communicated later this quarter. The ARCT-810 presentation is provided as Exhibit 99.1 and is described as furnished, not deemed filed or incorporated by reference into other securities law reports.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Presentation date: August 25, 2026
Exhibit number for ARCT-810 presentation: Exhibit 99.1
Cover page exhibit: Exhibit 104
+1 more
4 metrics
Presentation date
August 25, 2026
Date of ARCT-810 poster presentation at the 2026 Annual Symposium
Exhibit number for ARCT-810 presentation
Exhibit 99.1
Exhibit containing the ARCT-810 poster presentation
Cover page exhibit
Exhibit 104
Cover page provided in Inline XBRL format
Company telephone number
(858) 900-2660
Registrant’s telephone number at principal executive offices
Key Terms
Regulation FD, Ornithine Transcarbamylase Deficiency, mRNA Therapy, Inborn Errors of Metabolism, +1 more
5 terms
Regulation FD regulatory
"Item 7.01. Regulation FD Disclosure."
Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.
Ornithine Transcarbamylase Deficiency medical
"therapy ... in Adolescents and Adults with Ornithine Transcarbamylase Deficiency"
Ornithine transcarbamylase deficiency is an inherited metabolic disorder in which the liver cannot effectively remove ammonia, a toxic byproduct of protein breakdown, leading to dangerous ammonia buildup. For investors, it matters because the condition creates demand for specialized diagnostics, chronic treatments and potential one-time gene therapies; think of it like a broken household waste-removal system that requires ongoing fixes or a permanent repair, creating commercial and regulatory opportunities and risks.
mRNA Therapy medical
"Impact of ARCT-810 mRNA Therapy on Dietary Intake and Biochemical Data"
mRNA therapy uses messenger RNA — the cellular instruction molecules — to tell a patient’s cells to produce a desired protein, such as one that fights disease or corrects a malfunction. Think of it as delivering a short recipe so cells can make a medicine internally; this approach can be faster to design but depends on clinical success, manufacturing capacity and regulatory approval, all of which strongly affect investment risk and potential reward.
Inborn Errors of Metabolism medical
"Society for the Study of Inborn Errors of Metabolism"
Inherited genetic disorders that prevent the body from breaking down or using certain nutrients and chemicals, like a factory assembly line that can’t process specific parts. They matter to investors because they create lasting demand for specialized diagnostics, drugs and care; advances, approvals or pricing changes can reshape the commercial outlook for companies working on tests, therapies or services for these conditions.
Inline XBRL technical
"Cover Page to this on in Inline XBRL"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
FAQ
What did ARCT (Arcturus Therapeutics Holdings Inc.) announce regarding ARCT-810?
Arcturus announced it will present a poster on ARCT-810 mRNA therapy in adolescents and adults with ornithine transcarbamylase deficiency at the 2026 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism in Helsinki, Finland on August 25, 2026.
What future plans did ARCT disclose for the ARCT-810 program?
Arcturus stated that additional data and the regulatory plan for the ARCT-810 program are expected to be communicated later in the same quarter as the symposium presentation.
How is the ARCT-810 presentation by ARCT being made available to investors?
The ARCT-810 presentation is included as Exhibit 99.1. It is described as furnished under a Regulation FD disclosure item rather than filed, and is not incorporated by reference into other securities law reports.
What is the subject of ARCT’s ARCT-810 poster presentation?
The poster is titled “Impact of ARCT-810 mRNA Therapy on Dietary Intake and Biochemical Data in Adolescents and Adults with Ornithine Transcarbamylase Deficiency,” focusing on clinical data in this patient population.
Where and when will ARCT present the ARCT-810 data?
Arcturus will present the ARCT-810 poster on August 25, 2026 at the 2026 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism, which will be held in Helsinki, Finland.
AI-generated analysis. How Rhea-AI works. Not financial advice.
